Deep Health AI India has approved its audited standalone and consolidated financial results for the financial year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 29, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported a consolidated net profit of ₹113.39 lakh for FY26, compared to ₹87.65 lakh in the previous year.

The standalone financial results for FY26 show a net profit of ₹129.91 lakh, a significant turnaround from the previous year. Revenue from operations for the year stood at ₹425.00 lakh, while other income was ₹424.02 lakh. The board also approved the appointment of M/s. Valawat & Associates Chartered Accountants as the Internal Auditor for the financial year 2026-2027.

The financial results include an exceptional item of ₹577.81 lakh recognized in the standalone accounts, primarily due to the acquisition of Oasis Ceramics Pvt. Ltd. under the Insolvency and Bankruptcy Code. The company faced delays in payment timelines, leading to the invocation of a bank guarantee amounting to ₹3.21 crore and the recognition of an exceptional loss based on management's assessment.

During the year, the company raised ₹39.97 crore through a Rights Issue. While ₹2.5 crore was utilized towards the stated objects, ₹37.47 crore was deployed for investments through recognized stock exchanges, a deviation ratified by shareholders in January 2026. The company also disposed of its investment in Hemonc Pharma Private Limited on March 28, 2026.

The Board of Directors of Deep Health AI India Limited , formerly known as Deep Diamond India Limited, convened a meeting on May 04, 2026, at its registered office located at 506-509, Fifth Floor, Apeksha, Plot No. 256, Sector 11, Udaipur, Rajasthan. The meeting commenced at 02:30 P.M. and concluded at 04:00 P.M. During the meeting, the board considered and approved a proposal to raise funds through a rights issue of fully paid-up equity shares to eligible existing shareholders.

Rights Issue Approval

The board approved raising funds through the issue of fully paid-up equity shares on a rights basis to the existing equity shareholders of the company, for an amount aggregating up to Rs. 25.00 crores (Rupees Twenty-Five Crores). The issue is subject to receipt of statutory and regulatory approvals in accordance with the provisions of the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws. The record date for determining eligible shareholders is yet to be determined and will be notified subsequently.

The key details of the proposed rights issue, as disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are as follows:

Rights Issue Committee Constituted

To give effect to the rights issue, the board constituted a Rights Issue Committee and authorised its members to decide on the terms and conditions of the issue. The committee's mandate includes, but is not limited to, the following:

• Determining the final issue size and amount
• Fixing the rights entitlement ratio and issue price
• Setting the record date and schedule of the rights issue
• Approving the letter of offer
• Appointment of intermediaries and legal counsel, if required
• Allotment of shares and other related matters

Draft Letter of Offer and Regulatory Filing

The board also approved the Draft Letter of Offer for fund raising by way of the rights issue and authorised the company to apply for in-principal approval for the rights issue of up to Rs. 25.00 crores under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcome of the board meeting was communicated to BSE Limited under Regulation 30 of the SEBI Listing Regulations. The disclosure was signed by Narayan Singh Rathore, Managing Director of the company.